Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas
- 5 April 2000
- journal article
- Published by Wiley in Brain Pathology
- Vol. 10 (2) , 249-259
- https://doi.org/10.1111/j.1750-3639.2000.tb00258.x
Abstract
Classification of high grade astrocytomas of children into genetic subtypes similar to the adult remains to be defined. Here we report an extensive characterization of 29 high grade pediatric astrocytomas, 7 WHO grade III and 22 WHO grade IV, for genetic alterations frequently observed in high grade adult astrocytomas occurring in either the p53/MDM2/p14ARF or Rb/CDK4/p16INK4a tumor suppressor pathways. In addition, we have assessed the contribution of EGFR overexpression and amplification and LOH for chromosome 10, two genetic alterations commonly associated with the development of de novo adult glioblastoma for their roles in the development of de novo astrocytomas of childhood. Our results suggest two major differences in the genetic pathway(s) leading to the formation of de novo high grade astrocytomas in children compared with those of the adult. Our findings show preferential inactivation of the p53 tumor suppressor pathway in > 95% of pediatric astrocytomas versus inactivation of the Rb tumor suppressor pathway in < 25% of the same tumors. In addition, de novo high grade pediatric astrocytomas lack amplification of the EGFR gene compared with EGFR amplification in one-third of adult glioblastomas. Since drug treatments and gene therapy strategies exploit specific genetic alterations in tumor cells, our findings have important implications for the future development of treatments for high grade pediatric astrocytomas.Keywords
This publication has 35 references indexed in Scilit:
- Genetic alterations in pediatric high-grade astrocytomasHuman Pathology, 1999
- Molecular Analysis of Microdissected de novo Glioblastomas and Paired Astrocytic TumorsJournal of Neuropathology and Experimental Neurology, 1999
- Alterations of the p16-pRb Pathway and the Chromosome Locus 9p21–22 in Non-Small-Cell Lung CarcinomasThe American Journal of Pathology, 1998
- PTEN mutations in gliomas and glioneuronal tumorsOncogene, 1998
- Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in GlioblastomasJournal of Neuropathology and Experimental Neurology, 1998
- Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomasActa Neuropathologica, 1997
- Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma MultiformeBrain Pathology, 1997
- Amplification and Overexpression of MDM2 in Primary (de novo) GlioblastomasJournal of Neuropathology and Experimental Neurology, 1997
- p53 gene mutations in pediatric brain tumorsMedical and Pediatric Oncology, 1995
- Glioblastoma multiforme in childrenJournal of Neurosurgery, 1976